NovoCure Limited - stock earnings
NVCR Upcoming estimated earnings
| Date | Actual / Estimated EPS | Low Revenue | Actual / Estimated Revenue | High Revenue |
|---|---|---|---|---|
| May 2, 2024 AfterMarket | -0.36 / -0.43 | - | 138.5 million / 134.1 million | - |
NVCR Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2024Q1 | -38.8 million USD | 138.5 million USD |
| 2023Q4 | -47.1 million USD | 133.8 million USD |
| 2023Q3 | -49.5 million USD | 127.3 million USD |
| 2023Q2 | -57.4 million USD | 126.1 million USD |
| 2023Q1 | -53.1 million USD | 122.2 million USD |
| 2022Q4 | -37.3 million USD | 128.4 million USD |
| 2022Q3 | -26.6 million USD | 131.0 million USD |
| 2022Q2 | -24.0 million USD | 140.9 million USD |
| 2022Q1 | -4.6 million USD | 137.5 million USD |
| 2021Q4 | -26.5 million USD | 133.2 million USD |
| 2021Q3 | -13.1 million USD | 133.6 million USD |
| 2021Q2 | -14.6 million USD | 133.5 million USD |
| 2021Q1 | -4.1 million USD | 134.7 million USD |
| 2020Q4 | 4.9 million USD | 144.0 million USD |
| 2020Q3 | 9.3 million USD | 132.7 million USD |
| 2020Q2 | 1.7 million USD | 115.9 million USD |
| 2020Q1 | 4.0 million USD | 101.8 million USD |
| 2019Q4 | 4.3 million USD | 99.2 million USD |
| 2019Q3 | 1.9 million USD | 92.1 million USD |
| 2019Q2 | -1.3 million USD | 86.7 million USD |
| 2019Q1 | -12.2 million USD | 73.3 million USD |
| 2018Q4 | -15.6 million USD | 69.7 million USD |
| 2018Q3 | -11.7 million USD | 64.8 million USD |
| 2018Q2 | -15.5 million USD | 61.5 million USD |
| 2018Q1 | -20.7 million USD | 52.1 million USD |
| 2017Q4 | -10.9 million USD | 53.7 million USD |
| 2017Q3 | -11.5 million USD | 50.1 million USD |
| 2017Q2 | -21.2 million USD | 38.4 million USD |
| 2017Q1 | -18.0 million USD | 34.9 million USD |
| 2016Q4 | -22.2 million USD | 30.2 million USD |
| 2016Q3 | -33.6 million USD | 21.7 million USD |
| 2016Q2 | -40.6 million USD | 17.9 million USD |
| 2016Q1 | -35.4 million USD | 13.1 million USD |
| 2015Q4 | -32.9 million USD | 12.4 million USD |
| 2015Q3 | -26.0 million USD | 9.0 million USD |
| 2015Q2 | -29.4 million USD | 6.5 million USD |
| 2015Q1 | -23.3 million USD | 5.2 million USD |
| 2014Q4 | -22.9 million USD | 3.8 million USD |
| 2014Q3 | -18.3 million USD | 4.4 million USD |
| 2014Q2 | ? USD | 7.3 million USD |
| 2013Q4 | -77.4 million USD | 10.4 million USD |
NVCR Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -207.0 million USD | 509.3 million USD |
| 2022 | -92.5 million USD | 537.8 million USD |
| 2021 | -58.4 million USD | 535.0 million USD |
| 2020 | 19.8 million USD | 494.4 million USD |
| 2019 | -7.2 million USD | 351.3 million USD |
| 2018 | -63.6 million USD | 248.1 million USD |
| 2017 | -61.7 million USD | 177.0 million USD |
| 2016 | -131.8 million USD | 82.9 million USD |
| 2015 | -111.6 million USD | 33.1 million USD |
| 2014 | -80.7 million USD | 15.5 million USD |
| 2013 | -77.4 million USD | 10.4 million USD |
NVCR
Price: $14.78
52 week price:
Earnings Per Share: -1.95 USD
P/E Ratio: -8.40
Exchange: NMS
Sector: Healthcare
Industry: Medical Devices
Volume: 542600
Ebitda: -3.9 millionMarket Capitalization: 1.6 billion